Until now, absolute uterine factor infertility has been the major untreatable form of female infertility. Uterus transplantation has recently proven to be the first successful treatment for absolute uterine factor infertility, with demonstration of live births. In this study, live donation uterus transplantation was performed in nine women. In total, 163 cervical biopsies (149 protocol, 14 follow-up) were taken to detect histopathological signs of rejection. Based on experience from animal experiments, we used a three-grade scoring system to evaluate biopsies systematically. Nine episodes of rejection were diagnosed in five patients: grade 1 in six episodes, grade 2 in two episodes, and grade 3 in one episode. Treatment decisions were based on histopathology, and all rejection episodes were reversed after treatment. The biopsies were reviewed retrospectively, and immunohistochemistry was performed to characterize the inflammatory infiltrates. A borderline category was introduced to avoid overtreatment of patients. Based on our review of all biopsies, we put forward a simple grading system for monitoring of rejection and to guide immunosuppressive treatment in uterus transplantation.
Introduction
Until now, absolute uterine factor infertility (AUFI) has been the major untreatable form of female infertility. Uterus transplantation (UTx) has recently proven to be the first option for treatment of AUFI, with the demonstration of successful live births (1).
Solid organ transplantation was introduced in clinical practice >50 years ago and is now an established procedure for many organs. To guide treatment in each individual case and to enable clinical studies, classification systems for rejection have been introduced and validated. In the field of kidney transplantation, the Banff classification system was introduced in 1991 and has been continuously reevaluated and updated (2) . Several other organ-specific classifications are also discussed at the Banff meetings (3) . There is a classification system in the field of vascularized composite allotransplantation (VCA) (4) , with hand/arm and face VCA being the most prevalent types. As with VCA, UTx is a nonvital transplantation, but it enhances patients' quality of life; however, compared with all other types of transplants, a major difference and advantage concerning UTx is its limited use. A uterus graft would preferably be removed once the desired number of children has been born, substantially reducing the usual risks of long-term immunosuppression. There are no available research data, in either animal UTx models or humans, to determine whether there is a risk with repeated pregnancies in a transplanted uterus. Experience with women who are pregnant and under immunosuppression after transplantation of other solid organs indicates that pregnancy under conditions of immunosuppression is safe for the offspring (5, 6) .
Women with AUFI who are candidates for UTx may lack a uterus from birth, as in uterine agenesis (MayerRokitansky-K€ uster-Hauser syndrome), or after hysterectomy at an early age, which is often a life-saving procedure following early stage cervical cancer or intractable peripartum hemorrhage. This type of infertility can also occur in a woman with a uterus but with a major congenital malformation or severe intrauterine adhesions, usually after infection or extensive curettage. The prevalence of AUFI is estimated to be %20 000 women of fertile age in a population of 100 million (7) . Apart from UTx, the only possibility for these women to have their own, genetically linked children is gestational surrogacy, which is not approved in most countries of the world for religious, ethical, or legal reasons.
We initiated a preclinical research project on UTx in 1999 with experiments performed in rodents (8, 9) , domestic animals, and nonhuman primates (10) in preparation for our human trial, which began in 2013. We developed a preliminary grading system for uterine allograft rejection based on evaluation of cervical biopsies obtained after allogeneic UTx in baboons. This grading system served as the knowledge base for evaluation of cervical biopsies from the patient cohort in the first human clinical UTx trial (11) (12) (13) .
The objective of the present study was to obtain data on the rejection patterns in uterine transplantation and to provide a preliminary grading system in a human setting. This is of interest because several transplant centers are starting human UTx trials.
Material and Methods

Patients
After thorough evaluation by a multidisciplinary team, nine patients were recruited to the study of live donor UTx. The study was approved by the Regional Human Ethics Committee and was registered at ClinicalTrials. gov (identifier NCT01844362). Data concerning the characteristics of donors and recipients, surgical outcome, and clinical data after transplantation were published previously (11) (12) (13) (14) . Briefly, the nine AUFI patients were transplanted using live donors. Two uteri were removed postoperatively because of uterine vessel thrombosis in one case and persistent intrauterine infection in the other case. Seven patients kept their uterine grafts; the first baby was delivered in September 2014 (13) , and the second baby was born 2 mo later (14) . The patients were numbered in the first published report (11) , and the same numbers are used in this report. HLA mismatches (HLA-A, -B, and -DRB1) for the seven successful transplantations varied between 1/0 and 3/2 (Table 1) . In this article, we report biopsy findings 3 years after UTx.
Immunosuppression
The immunosuppressive regimen essentially followed the protocols used after kidney transplantation at our center. Briefly, corticosteroids (500 mg Solu-Medrol; Pfizer) and anti-thymocyte globulins (ATG) on day 0 and day 1 (2.5 mg/kg body weight; Fresenius) were used for induction therapy, followed by mycophenolate mofetil (MMF; Cellcept; Roche) and tacrolimus (Prograf/Advagraf; Astellas) for 6-8 mo. Thereafter, the goal was tacrolimus monotherapy. Tacrolimus was aimed at 10-15 ng/mL for the first month and then at 5-10 ng/mL. Samples of patient serum were tested for the presence of HLA-specific antibodies using the LABScreen Mixed class I and II antibody screening kit (OneLambda, Canoga Park, CA). Positive samples were then analyzed further using the appropriate HLA class I and/ or II LABScreen single-antigen kit (OneLambda). The beads were analyzed using the Luminex 100 platform (Luminex, Austin, TX).
Biopsy-proven rejection was treated by temporary elevation of immunosuppression and a short course of steroids. For cases in which rejection was seen after withdrawal of MMF or in a biopsy after 6-8 mo, azathioprine (Imurel; Orion Pharma) and prednisolone (Prednisolon; Pfizer) were added as maintenance immunosuppression. In two patients with early rejection (patients 7 and 8), the basal immunosuppression was increased continuously ( Table 2) .
Follow-up and biopsies
Patients were followed with regular clinical visits, and simple cervical biopsies were executed according to the planned UTx protocol. Biopsies were generally obtained at the following time points: 1, 2, and 4 weeks after transplantation and thereafter on a monthly basis. If rejection was seen in biopsies, follow-up biopsies were taken on a weekly basis (i.e. at intervals of 5-8 days) until histology normalized. All biopsies were taken from the cervix close to the cervical canal, and on two occasions, needle biopsies (SuperCore biopsy instrument 16ga 920 cm; Argon Medical Devices, Inc., Askim, Sweden) were obtained from the endomyometrium to rule out rejection in the uterine corpus.
In addition to biopsies, the patients were followed by visual inspection of the cervix, with bacterial culture, ultrasound measurements of the uterine arterial blood flow, and an estimation of the endometrial and myometrial thickness.
Histology and immunohistochemistry
Biopsies (2 9 4 mm to 4 9 6 mm) were put in formalin, transported to the laboratory, postfixed under constant shaking for at least 2 h, embedded in paraffin, sectioned (3-4 lm), and stained with hematoxylin and eosin and with van Gieson. All biopsies were assessed during the clinical trial by two pathologists (J.M. and O.N.) and then reevaluated by two pathologists (J.M. and V.B.). Biopsies were immunostained for C3c (A0062; Dako, Copenhagen, Denmark), C5b-9 (M0777; Dako), CD3 (N1617; Dako), CD56 (IR628; Dako), CD20 (M0775; Dako), CD68 (N1576; Dako), and C4d (ab 58781; Abcam, Cambridge, UK) using an automated procedure-the EnVision Flex high pH (Link) detection kit (K8000; Dako)-to characterize the cellular infiltrates and to evaluate possible humoral rejection patterns. All biopsies diagnosed as rejection (n = 13) and donor biopsies (n = 5) were stained, as were selected biopsies that were diagnosed as normal (n = 8) or borderline changes (n = 10).
Biopsies were assessed for the presence or absence and extent of inflammatory infiltrates, interface inflammation, endothelialitis, microvascular inflammation, and epithelial changes such as apoptotic bodies, spongiosis, thickness and dysplasia. Immunohistochemical stains for CD3, CD20, CD68, and CD56 were evaluated semiquantitatively using printed templates of high-power fields containing 10, 25, 50, 100, 200, or 500 circles equaling lymphocytes in size. The number of cells in the most DSA positive 1 year after uterus removal but negative at the time of biopsies.
densely populated high-power field was estimated by two of the investigators (J.M. and V.B.) by comparing visual impressions with templates. C4d, C3c, and C5b-9 were assessed according to the Banff grading system for C4d staining in renal transplants biopsies (0, <10%, 10-50%, and >50% of capillaries with circumferential endothelial staining).
Results
Morphological findings and proposed grading system
In total, 163 biopsies were performed within the first 36 mo in seven patients. To obtain a preliminary classification system, we decided to reevaluate all biopsies to detect repetitive histological patterns and to define the lowest threshold for histopathological diagnosis of rejection. Biopsies showed variable amounts of patchy, focal, or diffuse mixed inflammatory infiltrates, with lymphocytes predominating, located at the epithelial-stromal interface or extending into the cervical stroma. More pronounced inflammation was associated with surface erosion or occasionally even ulceration. Thirteen biopsies (8.0%) in five patients showed rejection, and 15 biopsies (9.2%) in five patients were evaluated as borderline changes, whereas 135 (82.8%) were normal. Microcirculatory inflammation or inflammation in larger G2  G0  G0  G0  G0  G0  -G0  G0  G0   Pat 2  INF,ISC  INF, ISC  INF, ISC  INF 
All patients received induction therapy with 2 doses antithymocyte globulin 2 mg/kg and 2 doses Solu-Medrol. All biopsies showing rejection (13) or borderline changes (15) are displayed, but repetitive normal biopsies have been omitted to keep the table as simple as possible. Patient 3 had steroid resistant rejection (G1-G3) during a 3-month period (months 28-31). Solu-Medrol and later antithymocyte globulin was given. She also had increased maintenance IS (tacrolimus and azathioprine). w, week; mo, month; B, borderline changes; G, rejection Grade; HYST, hysterectomy; yellow box, pregnant; INF, infection; ISC, ischemia; MC, miscarriage; #, diagnosis changed at re-evaluation, original diagnosis in parenthesis; Em, endometrial biopsy; , tacrolimus; , MMF; , azathioprine; , corticosteroids; , corticosteroids increased; , same regimen as previous period; , Solu-Medrol; , antithymocyte globulin. stromal vessels (endothelialitis) was not a feature in any of the biopsies. Based on these observations, all episodes of rejection were diagnosed as being cellular. In addition, C4d staining was negative in all biopsies investigated, and none of the patients had donor-specific antibodies (Table 1) . Staining for CD3, CD20, and CD68 showed T cell-dominant inflammation, but staining was not considered necessary for routine clinical practice. Detailed results of immunostaining are discussed subsequently. By analogy with other transplant-rejection classifications, we created a borderline category indicating inflammation of uncertain significance to avoid overtreatment of patients. The rejection grading system is described below and summarized in Table 3 .
Morphological findings in nonrejecting uterus transplants: The normal ectocervical mucosa is composed of stroma covered by a layer of nonkeratinizing squamous epithelium and contains variable amounts of inflammatory cells. In the uncomplicated transplant setting, the amount of inflammatory cells is usually low ( Figure 1A ).
Borderline changes: At the interface between the squamous epithelium and the stromal layer, there are a few small, nonconfluent, nested foci of inflammation, with lymphocytes predominating. This is frequently accompanied by intercellular edema. In the superficial stromal layer, minimal inflammation is seen, which is mostly restricted to the papillary stroma ( Figure 1B ).
Grade 1 (mild) rejection:
A mild mixed inflammatory cell infiltrate dominated by lymphocytes is seen at the interface of the superficial stroma and basal epidermal layer. This infiltrate can be continuous or patchy. Only single epithelial apoptotic bodies are seen ( Figure 1C ).
Grade 2 (moderate) rejection: A moderate continuous interface inflammatory cell infiltrate is seen with intraepidermal influx (exocytosis) of inflammatory cells, dominated by lymphocytes and with some neutrophils. The surface epithelium may show focal reduction in thickness, edema, and occasional epithelial apoptotic bodies. There is mixed stromal inflammation and edema ( Figure 1D ).
Grade 3 (severe) rejection: There is a significant diffuse, mixed inflammatory cell infiltrate dominated by lymphocytes, with the presence of neutrophils and eosinophils and several epithelial apoptotic bodies. Epithelial erosions and/or ulcerations are seen focally, and necrotic areas can be observed. The stromal infiltrate is dense and continuous ( Figure 1E ).
The rejection patterns are illustrated schematically in Figure 2 . Initial biopsy evaluation and outcome All biopsies were evaluated and reported to the clinicians within 24 h. Two patients had no rejections; of those, one had a healthy baby (patient 4), and the other patient (patient 6) is still waiting for in vitro fertilization to be successful. Three patients had a single rejection episode (grades 1-2), and all of them delivered healthy children (patients 1, 5, and 7). Patients 1 and 7 had early rejections (grade 2 and 1, respectively), and patient 5 had a late rejection (grade 2) during pregnancy. The remaining two patients (patients 3 and 8) had several rejection episodes. Patient 8 had three early and one late grade 1 rejection and had a healthy baby. Patient 3 was diagnosed with a late and persistent rejection episode after miscarriage at week 15. She is still trying to become pregnant and has not had further rejections 10 mo after the last biopsy-proven rejection (for details, see Table 2 ). Follow-up biopsies after treatment showed reduced inflammation and thus a normalized morphology ( Figure 1F ).
The three early rejection episodes were seen in weeks 2 and 3. There were two episodes at 3 and 4.5 mo, and the remaining rejection episodes were late, >10 mo after transplantation. Borderline changes were diagnosed on 15 occasions in five patients (Table 2 ). In three of these, the original diagnosis was rejection (grade 1) and thus was downgraded after reclassification.
Endomyometrial biopsies
On two occasions, myometrial biopsies were performed to exclude rejection in the uterine body. They showed normal myometrium almost devoid of inflammatory infiltrates, unremarkable vessels, and normal endometrium with few infiltrating lymphocytes, within normal limits ( Figure 3 ).
Immunohistochemistry
Biopsies that were negative for rejection showed a varying number of CD3-positive T cells, located mainly at the interface between the epithelium and stroma, whereas B cells were absent ( Figures 4A and B , Table 4 ). CD68-positive macrophages were scattered and diffusely distributed in the stroma. No CD56-positive NK cells were seen. Protocol biopsies classified as negative for rejection had a low number of T cells and a few B cells, mainly at the epithelial-stromal interface, with single NK cells in the basal epithelial cell layer. Macrophages were slightly increased and diffusely distributed in the stroma. Biopsies diagnosed as rejection had an increased number of T cells and B cells (Figures 4C and D) , with infiltration of mainly T cells in the epithelium. NK cells were few in number, whereas macrophages were not increased and still diffusely distributed in the stroma. B cells were markedly increased in biopsies with rejection compared with borderline cases. The number of T cells increased in grade 2 and 3 rejections but not in grade 1 rejections compared with borderline rejection (Table 4) . Follow-up biopsies showed reduction of the inflammatory infiltrate and epithelial regeneration (Figures 4E and F) . C4d, C3c, and C5b-9 immunostainings were completely negative in all cases.
Discussion
In this paper, we present our morphological findings in cervical biopsies and provide a provisional system for grading of rejection in human uterine transplants. The biopsies were obtained from the ectocervical surface close to the cervical canal to diagnose rejection in uterus transplants from accessible tissue. This can be performed as an ordinary outpatient gynecological procedure, with no pain felt by the patients, because the uterus is denervated after transplantation. We chose to take biopsies from the ectocervix because it is accessible for visual inspection and available for biopsy. Previous experiments on nonhuman primates had shown that this technique is feasible and safe (10) . In their case report on the first deceased donor UTx, Ozkan et al took biopsies from the vagina and, after 3 mo, from the endometrium (15) . We consider biopsies from the vaginal cuff or endometrium to be technically more demanding, and-importantly-these biopsy sites have not been evaluated for detection of rejection in any animal UTx model.
The proposed grading system may serve as a basis for guidance of immunosuppressive and antirejection treatment. Its relevance is indicated by the fact that six of seven successfully transplanted patients became pregnant and five healthy babies have been born so far. The rejections have generally been mild, and only one patient Previous studies in small and large animal models by our group have shown that UTx is a fairly safe procedure, resulting in positive outcomes with pregnancies and normal offspring (8, 9, (16) (17) (18) . A transplantation model in baboons was developed to evaluate the pattern of uterus rejection, and a preliminary grading system was obtained (10) . This system was used in the human research trial. On reevaluation of all biopsies, we concluded retrospectively that some rejections were likely overcalled because minimal inflammation was initially interpreted as grade 1 rejection in three of the biopsies. Follow-up biopsies were normal within 1-2 weeks. To avoid overtreatment in future trials, and by analogy with evaluation of kidney transplants, we created a borderline category. We believe that this category is justified, at least in initial studies of human UTx, to avoid overimmunosuppression. Perhaps this category can be eliminated in the future as more data and experience become available.
In total, nine rejection episodes were diagnosed in five patients (13 biopsies) and treated successfully with increased immunosuppression (Table 2) . Follow-up biopsies showed normalization of histology in the biopsies after 1-3 weeks. Importantly, all rejections were asymptomatic, and we could not detect any clinical signs of changed ultrasound parameters or cervical abnormalities. Two patients did not have any rejections, and three patients had only one rejection (not including borderline changes), whereas two patients had several rejection episodes. One of them showed grade 1 rejection only, whereas the other patient had multiple grade 2 and 3 rejections over a 3-mo period after miscarriage at gestational week 15 due to chorioamnionitis. Following treatment, she had normal findings in protocol biopsies over 8 mo. She had no previous rejections, and it is possible that the spontaneous abortion induced an inflammatory response. This could be due to tissue damage or, more likely, to alterations in steroid hormone levels. The number or severity of rejections did not appear to influence the possibility of becoming pregnant or of maintaining pregnancy; therefore, one might argue that histological findings in cervical biopsies are irrelevant for outcome after UTx. Nevertheless, no other clinical or biochemical parameter to monitor potential rejections after UTx has been developed so far, and cervical biopsies are relatively easy to obtain without putting the patient at risk. Future studies will need to determine whether the uterus is an immunologically inert organ that does not require histological guidance after transplantation; however, this has not been true for any other organ studied so far. One of the patients (patient 5) may have been overtreated because reclassification of her biopsies changed her diagnosis from grade 1 to borderline in two early biopsies (at 1 week and 6 mo), and she received increased basal immunosuppression.
We chose to develop and use our own grading system for cervical biopsies because this tissue is different from allografts containing skin, for which the Banff composite tissue allotransplantation/VCA classification system is recommended (Table 3 ) (4). We are also aware of the classification system used by Bergfeld et al (19) for mucosal biopsies in a face transplant ( Table 3 ). Both of these classifications highlight perivascular inflammation, which was not a feature of our study. We also added a borderline category to avoid overcalling rejection, and that is not included in these grading systems. The borderline category may be comparable to grade 1 rejection in other systems (Table 3) . Consequently, a higher frequency of acute rejection has been reported for skin and mucosal biopsies. Bergfeld et al reported rejection frequencies of 36% in skin biopsies and 49% in mucosal biopsies from their single face transplant case compared with our 8%. Our biopsies were generally protocol biopsies (n = 149) except for follow-up biopsies (n = 14) after treatment of rejection, whereas Bergfeld et al included both protocol biopsies and biopsies for cause. Clinically, they had only two rejection episodes. In hand transplantation, a rejection rate of 85% was reported during the first year after transplantation (20) . This implies that the Banff scoring system might overcall rejection if biopsy findings alone are used to determine rejection. Because there is a lack of clinical signs of rejection, we have to rely on biopsy findings in UTx; therefore, it is important not to overcall rejection. We performed immunostainings that showed significant infiltration of T and B cells at the epithelial-stromal interface but no significant amounts of macrophages or NK cells. Interpretation of these data is difficult because of the limited number of patients and biopsies. C4d staining was negative in all biopsies showing rejection or borderline changes. Furthermore, we did not observe microvascular inflammation or thrombi, so we have no evidence of humoral rejection in this particular cohort of patients.
In summary, we propose a preliminary rejection grading system for cervical biopsies from uterus transplants that can serve as guidance for immunosuppressive treatment in future clinical trials involving UTx.
